INMB Inmune Bio Inc

Price (delayed)

$1.36

Market cap

$36.16M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.67

Enterprise value

$16.31M

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 4

INmune Bio, Inc. is a publicly traded, clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms. The ...

Highlights
INMB's quick ratio has soared by 62% YoY and by 35% QoQ
The EPS has increased by 13% year-on-year and by 10% since the previous quarter
The gross profit has shrunk by 100% QoQ and by 100% YoY
The revenue has dropped by 100% since the previous quarter and by 100% year-on-year

Key stats

What are the main financial stats of INMB

INMB stock price

How has the Inmune Bio stock price performed over time
Intraday
3.03%
1 week
-4.23%
1 month
-8.11%
1 year
-82.18%
YTD
-12.82%
QTD
20.35%

Financial performance

How have Inmune Bio's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$43.29M
Net income
-$41.6M
Gross margin
N/A
Net margin
N/A
The gross profit has shrunk by 100% QoQ and by 100% YoY
The revenue has dropped by 100% since the previous quarter and by 100% year-on-year
Inmune Bio's net income has increased by 9% QoQ
The company's operating income rose by 9% QoQ but it fell by 4.3% YoY

Price vs fundamentals

How does INMB's price correlate with its fundamentals

Growth

What is Inmune Bio's growth rate over time

Valuation

What is Inmune Bio stock price valuation
P/E
N/A
P/B
1.84
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has increased by 13% year-on-year and by 10% since the previous quarter
The P/B is 46% lower than the 5-year quarterly average of 3.3
INMB's equity is down by 34% year-on-year and by 17% since the previous quarter
The revenue has dropped by 100% since the previous quarter and by 100% year-on-year

Efficiency

How efficient is Inmune Bio business performance
INMB's ROA is down by 44% YoY
Inmune Bio's ROE has decreased by 43% YoY

Dividends

What is INMB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for INMB.

Financial health

How did Inmune Bio financials performed over time
INMB's quick ratio has soared by 62% YoY and by 35% QoQ
The current ratio has surged by 61% year-on-year and by 19% since the previous quarter
The debt is 92% smaller than the equity
The debt to equity has surged by 100% since the previous quarter
The debt has increased by 46% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.